Global Epigenetics Market - 2022-2029

Global Epigenetics Market - 2022-2029

Market Overview

The global epigenetics market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

The field of epigenetics investigates cells regulation of gene function without altering the DNA sequence. Epigenetic alterations to DNA control whether or not genes are activated. These alterations are connected to DNA and do not alter the order in which the DNA building blocks are arranged. The epigenome, which is all of the modifications that control how genes are expressed inside a cell's entire set of DNA, is referred to as the genome. Epigenetic modifications affect the synthesis of proteins in cells by influencing the decision of which genes are activated or inactive. Each cell only generates the proteins required for it to operate thanks to this control.

Market Dynamics

The major factors driving the global epigenetics market the number of people obtaining cancer diagnoses has significantly increased globally, the rise of elderly people is expected to rise, accelerating market expansion.

Both the use of epigenetics in conditions other than cancer and the number of academic, pharmaceutical, and biotechnology companies working together on epigenetics research are expanding.

The number of people obtaining cancer diagnoses have significantly increased globally is expected to drive the market’s growth.

According to the World Health Organization, cancer will be the primary cause of death for roughly 10 million people worldwide in 2020 or one in every six fatalities. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections, including the human papillomavirus (HPV) and hepatitis, are thought to cause 30% of cancer cases. If caught early and appropriately treated, many tumors are curable.

According to the International Agency for Research on Cancer (IARC) 2020 report, 1 in 5 individuals worldwide will develop cancer at some point in their lives, and 1 in 8 men and 1 in 11 women will pass away. According to these latest projections, more than 50 million people are alive five years after a cancer diagnosis. Globally aging populations and socioeconomic risk factors continue to be the main causes of this rise. One in four cancer diagnoses among women worldwide is breast cancer.

Expensive cost is expected to hamper the market’s growth.

However, the growing expenditure on instruments is further projected to impede the growth of the epigenetics market in the targeted period.

COVID-19 Impact Analysis

The epigenetics market benefited from COVID-19. A few therapeutic combinations have been attempted to assist people in surviving the coronavirus, even though there is no clinically approved medication or vaccine to treat coronavirus infection. Furthermore, it has been demonstrated that certain antiviral drugs, such remdesivir, rapamycin, and ribavirin, as well as epigenetic drugs like BRD4 inhibitors, DNMT1 inhibitors, and HDAC inhibitors, limit virus activity.

Researchers have started understanding how epigenetics may restrict viral multiplication to create vaccinations and treatments that target a virus's replicating machinery. Therefore, it is anticipated that the epigenetics industry will gain from increased epigenetic studies and knowledge of epigenetic drugs for treating coronavirus infection.

Even though there are many potential treatments, more study is urgently required to find a workable vaccine or more secure chemotherapy drugs, such as epigenetic therapies, to stop this viral pandemic and develop pre- and post-exposure COVID-19 prophylaxis. This will result in greater use of epigenetics in the search for COVID-19 infection treatments.

Segment Analysis

The pharmaceutical and biotechnology industry segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pharmaceutical and biotechnology industry segment is the highest market holder in the global epigenetics market. Programs for the discovery and development of epigenetic drugs have recently received much interest and funding. The potential for developing novel treatment approaches that can successfully repair transcriptional and epigenetic aberrations prevalent in many human illnesses is what motivates this. The key income source for academic and research institutes is the rising use of epigenetics products in government research facilities and university laboratories.

It is anticipated that pharmaceutical and biotechnology companies will rapidly grow throughout the projected period. To create cutting-edge treatment methods, startups and SMEs are investing in the epigenetics industry. In November 2021, Chroma Medicine announced plans to develop an epigenetic editor that might alter how genes manufacture proteins. Funding for this startup company of USD 125 million has come from Newpath Partners, Atlas Venture, and other investors.

The startup wants to make medicines using gene-editing methods. The company wants to develop drugs that can alter the epigenome using gene-editing methods, which will be a breakthrough method of treating genetic diseases.

Geographical Analysis

North America holds the largest market share in the global Epigenetics market.

North America dominates the global epigenetics market primarily due to its large population, excellent medical infrastructure, and high-income levels. Since many mammalian proteins, including growth hormones, insulin, antibodies, and vaccines, are manufactured industrially, the demand for protein expression systems is anticipated to rise along with rising spending by industries in product research and development. Additionally, there is a rising need for the creation of cancer medicines in the U.S., and significant investments are being made in studying cancer genomes, which is anticipated to fuel the expansion of this market in North America.

For instance, according to the United States National Institute of Health, $1,098 million had been allocated for cancer genomics research as of December 2021. In 2022, the funding will be anticipated to total USD 1,152 million. Increased use of epigenetics in research due to increased funding for cancer genomics in the United States is anticipated to fuel market expansion over the forecast period.

In addition, the rising incidence of cancer in the U.S., the increasing need for cancer treatments, and the significant investments being made in raising awareness of cancer genetics are all expected to contribute to the market's growth in the nation. The second greatest cause of death in the nation is cancer. Around 602,350 Americans will die from cancer in the U.S. in 2020. Additionally, rising funding for cancer genomics in the U.S. will lead to more researchers using epigenetics in their studies, which will spur market growth throughout the forecast period.

Geographical Analysis

North America holds the largest market share in the global Epigenetics market.

North America dominates the global epigenetics market primarily due to its large population, excellent medical infrastructure, and high-income levels. Since many mammalian proteins, including growth hormones, insulin, antibodies, and vaccines, are manufactured industrially, the demand for protein expression systems is anticipated to rise along with rising spending by industries in product research and development. Additionally, there is a rising need for the creation of cancer medicines in the U.S., and significant investments are being made in studying cancer genomes, which is anticipated to fuel the expansion of this market in North America.

For instance, according to the United States National Institute of Health, $1,098 million had been allocated for cancer genomics research as of December 2021. In 2022, the funding will be anticipated to total USD 1,152 million. Increased use of epigenetics in research due to increased funding for cancer genomics in the United States is anticipated to fuel market expansion over the forecast period.

In addition, the rising incidence of cancer in the U.S., the increasing need for cancer treatments, and the significant investments being made in raising awareness of cancer genetics are all expected to contribute to the market's growth in the nation. The second greatest cause of death in the nation is cancer. Around 602,350 Americans will die from cancer in the U.S. in 2020. Additionally, rising funding for cancer genomics in the U.S. will lead to more researchers using epigenetics in their studies, which will spur market growth throughout the forecast period.

Competitive Landscape

The Epigenetics market is moderately competitive with local and global companies’ presence. AbClam PLC, Diagenode Inc, Active Motiff, Illumina Inc, New England Biolabs, Bio-Rad, Merck &co, Merck Millipore, QIAGEN, Thermo Fisher and among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in April 2021, The ""SARS-CoV-2 Full-length Genome Sequencing"" service has been introduced by Eurofins Genomics India, a top supplier of genomic goods and services. This new next-generation sequencing (NGS) service enables end-to-end monitoring of the coronavirus genome sequence and mutational drift.

AbClam PLC.

Overview:Abcam Plc (Abcam) is a provider of life science research instruments for the molecular analysis of living cells to comprehend a variety of illness situations. The business creates and sells antibodies as well as associated goods. Primary and secondary antibodies, immunoassay kits and reagents, tools for imaging cells and tissues, cellular and biochemical assays, proteins and peptides, proteomics tools, activators, agonists, antagonists, and inhibitors, as well as lysates, are all part of its product line. The products made by Abcam help researchers in the biological sciences and veterinary sciences find proteins.

Product Portfolio:

Recombinant Anti-CREBBP + KAT3B / p300 antibody [EPR23495-276] (ab275379): Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply. Rabbit monoclonal [EPR23495-276] to CREBBP + KAT3B / p300. Suitable for: WB, Flow Cyt (Intra), ICC/IF, IHC-P.

The global Epigenetics market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.